Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600E or NRAS Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Array BioPharma; Novartis
- 25 May 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
- 10 Jun 2017 Biomarkers information updated
- 26 May 2017 Planned End Date changed from 30 Jun 2017 to 30 Jun 2018.